The Master Protector Glutathione is unique because it can neutralize free radicals directly
We do not know what that means for strength, stability and/or independence
People who have had bariatric surgery Previous bariatric surgery, particularly gastric bypass, permanently alters the digestive anatomy in ways that reduce B12 absorption
Results Preparation of the D-CuP The dimeric peptide D-P was synthesized through the covalent conjugation of two glycyl-l-histidyl-l-lysine (GHK) tripeptide moieties utilizing lysine as the bridging molecule (Fig
Trials are now consistently reporting 1523%: Tirzepatide (SURMOUNT-1): up to 22.5% mean weight loss (72 weeks) Semaglutide dose escalation (STEP UP): 20.7% mean weight loss with 7.2 mg (72 weeks) and ~1 in 3 achieved 25% weight loss 2) Focus is shifting from weight hard outcomes Cardiovascular protection in obesity (no diabetes) SELECT: MACE reduced with semaglutide 2.4 mg 6.5% vs 8.0% events HR 0.80 Kidney + survival benefit in CKD FLOW: semaglutide reduced major kidney outcomes HR 0.76 Also reduced MACE (HR 0.82) and all-cause death (HR 0.80) Sleep apnea is now metabolic SURMOUNT-OSA: tirzepatide improved apnea burden Treatment difference ~20 to 24 AHI events/hour (52 weeks) 3) Biology extends beyond appetite + glucose These therapies influence: inflammation and adipose remodeling vascular and renal pathways cardiometabolic risk clustering 4) Whats next is bigger than GLP-1 alone The pipeline is moving toward: multi-agonists improved pharmacokinetics + oral options precision selection by phenotype expansion into new indications (neuroinflammation, addiction biology, etc.) Clinical takeaway: GLP-1 therapies are transitioning from glycemic agents to disease-modifying cardiometabolic medicines
The injectable GLP-1 medications will drop to $245 per month for patients on Medicare or Medicaid who utilize them to treat medical conditions such as diabetes that have already been approved by the FDA
